Products for Research Use Only

Saracatinib

CAT: 0013-GTR19162320-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19162320-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
A potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively; displays high selectivity over a range of kinases (Csk, VEGFR-2, Flt-4, EGFR, and PDGFR) ; exhibits potent inhibition of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo.Breast Cancer Phase 2 Clinical (In Vitro) :Saracatinib (AZD0530), an orally available Src inhibitor, demonstrates potent antimigratory and anti-invasive effects in vitro, and inhibits metastasis in a murine model of bladder cancer. Antiproliferative activity of Saracatinib varies between cell lines (IC50 of 0.2-10 μM) . Saracatinib potently inhibits the proliferation of Src3T3 mouse fibroblasts and demonstrates variable antiproliferative activity in a range of human cancer cell lines containing endogenous Src. Sub micromolar growth inhibition of five of the human cancer cell lines tested with Saracatinib (tumor types: colon, prostate, lung, and leukemia) is observed with IC50 values of 0.2-0.7 μM. In 3-day MTS cell proliferation assays, Saracatinib inhibits proliferation of the Bcr-Abl-driven human leukemia cell line K562 with an IC50 of 0.22 μM. In the microdroplet migration assay, Saracatinib reduces the migration of human lung cancer A549 cells in a concentration-dependent manner (IC50 0.14 μM) . (In Vivo) :Saracatinib (AZD0530) treatment potently inhibits the proliferation of subcutaneously transplanted Src3T3 fibroblasts in mice and rats in a dose-dependent manner. In both models, significant inhibition of tumor growth is seen at doses ≥6 mg/kg/day (60% inhibition in mice and 98% inhibition in rats versus animals treated with vehicle) and, at the maximum doses investigated, complete tumor growth inhibition is observed (100% inhibition at 25 mg/kg/day in mice and 10 mg/kg/day in rats) .
CAS Number
379231-04-6
Product Name Alternative
AZD0530 | AZD-0530 | AZD 0530
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 32 mg/mL
Smiles
CN1CCN (CCOC2=CC3=NC=NC (NC4=C5OCOC5=CC=C4Cl) =C3C (OC6CCOCC6) =C2) CC1
Molecular Formula
C27H32ClN5O5
Molecular Weight
542.0265
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
4-Quinazolinamine, N- (5-chloro-1,3-benzodioxol-4-yl) -7-[2- (4-methyl-1-piperazinyl) ethoxy]-5-[ (tetrahydro-2H-pyran-4-yl) oxy]-

Popular Products